Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular ...

CatalYm today announced the presentation of the first preclinical data demonstrating that the company's clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug ...

Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation ...

CDR-Life today announced the presentation of data for its novel T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations ...

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

Alector has completed subject enrolment in the 76-week, randomised, Phase II PROGRESS-AD trial, which is assessing the ...